Financial Review: Palatin Technologies (OTCMKTS:PTNT) vs. Ampio Pharmaceuticals (NYSE:AMPE)

Insider & Institutional Ownership

11.5% of Palatin Technologies shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 7.1% of Palatin Technologies shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Palatin Technologies and Ampio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palatin Technologies	N/A	N/A	-365.57%
Ampio Pharmaceuticals	N/A	N/A	N/A

Volatility & Risk

Palatin Technologies has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 7.65, indicating that its stock price is 665% more volatile than the S&P 500.

Valuation & Earnings

This table compares Palatin Technologies and Ampio Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palatin Technologies	$4.49 million	49.41	-$29.74 million	($1.55)	-5.50
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02

Ampio Pharmaceuticals has lower revenue, but higher earnings than Palatin Technologies. Palatin Technologies is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.